Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07137052 | Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma | recruiting | — | 732 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07201337 | Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma. | active not recruiting | Phase 3 | 700 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07788950 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | not yet recruiting | Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07789158 | Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 269 | Fudan UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04456322 | Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 381 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06016920 | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 110 | Nykode Therapeutics ASAINDUSTRY | 7 | Aug 26, 2026 | clinicaltrials |
| NCT07392580 | Intralesional Chemotherapy (IC): Cisplatin + Epinephrine | recruiting | Phase 2 | 20 | University of MiamiOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784855 | Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer | not yet recruiting | N/A | 180 | West Virginia UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04910347 | Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 57 | Yonsei UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07780877 | Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer | not yet recruiting | Phase 2 | 85 | Fudan UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781072 | Sintilimab Plus Hypofractionated Radiotherapy Followed by Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781358 | Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. | recruiting | Phase 2 | 25 | Hongmeng YuOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT01893307 | Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer | active not recruiting | Phase 3 | 440 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04576091 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer | active not recruiting | Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05245682 | Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer | active not recruiting | Early Phase 1 | 10 | Emory UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06769698 | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT07225855 | Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer and Their Family Caregivers | recruiting | N/A | 36 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT07778368 | A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | Shanghai East HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07778615 | Immunohistochemical Expression of Cyclin D1 in Oral Squamous Cell Carcinoma: Relationship With Clinicodemographic and Histopathological Features | completed | — | 34 | Sohag UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07778732 | Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 32 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05724602 | Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma(RAVINA) | terminated | Phase 2 | 13 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Aug 20, 2026 | clinicaltrials |
| NCT06223568 | Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07636499 | Selective Neck Dissection Under Multimodal Assessment for N3 Nasopharyngeal Carcinoma After Radiotherapy | active not recruiting | Phase 1 | 50 | Guiquan ZhuOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00336063 | Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 4 | Aug 19, 2026 | clinicaltrials |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications(POTENTIATE) | terminated | Phase 1 | 85 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06508606 | AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 20 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06931743 | The Application of Electrical Stimulation in Postoperative Pain Management of Thyroid Surgery | recruiting | N/A | 668 | Xiaonan HuangOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT06239220 | PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | recruiting | Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06477003 | Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer(OUSCCMOTORX) | suspended | N/A | 100 | University of OklahomaOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06995508 | Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial | recruiting | Phase 2 | 66 | Roswell Park Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07182149 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | recruiting | Phase 1 | 150 | Normunity AccelCo, Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03650764 | Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 43 | Washington University School of MedicineOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04333537 | Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | recruiting | Phase 2 / Phase 3 | 686 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT05423197 | 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC | withdrawn | Phase 2 | 0 | Andrei IagaruOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06532279 | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | recruiting | Phase 2 | 98 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07441681 | Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin | recruiting | Phase 3 | 454 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07766889 | Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03283605 | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | completed | Phase 1 / Phase 2 | 33 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 27, 2026source: clinicaltrials